Novartis (NYSE: NVS) reported Q3 EPS of $1.23, $0.04 better than the analyst estimate of $1.19. Revenue for the quarter came in at $12.13 billion versus the consensus estimate of $12.24 billion.Novartis reaffirmed FY2016 guidance.

Strong pipeline progress with key data readouts, filings and regulatory decisions in Q3

• LEE011 plus letrozole demonstrated superior PFS as first-line treatment of HR+/HER2-advanced breast cancer vs. letrozole alone; granted FDA Breakthrough Therapy designation
• BAF312 in SPMS3 met primary endpoint, significantly reducing risk of disability progression
• AMG 334 met primary endpoint in first Phase III episodic migraine study
• Ilaris received three new FDA approvals for Periodic Fever Syndromes
• Sandoz biosimilar etanercept, Erelzi, received FDA approval

Entresto (USD 53 million in Q3) grew steadily; FY sales guidance of ~USD 0.2 billion confirmed

Continuing to invest in Alcon growth plan

• Contact lenses delivered another quarter of growth; Dailies Total1 Multifocal launches in US and EU expected to continue growth trajectory
• Innovation continued to accelerate in Surgical with FDA approvals for CyPass, UltraSert Toric IOL

The PDF could not be displayed inside the page, click here to open.

For earnings history and earnings-related data on Novartis (NVS) click here.